Adamson, C. et al. (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal, 43(41), pp. 4406-4417. (doi: 10.1093/eurheartj/ehac481) (PMID:36029309) (PMCID:PMC9622300)
![[img]](https://eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
278498.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. 1MB |
Abstract
Aims: Obesity is common and associated with unique phenotypic features in heart failure with preserved ejection fraction (HFpEF). Therefore, understanding the efficacy and safety of new therapies in HFpEF patients with obesity is important. The effects of dapagliflozin were examined according to body mass index (BMI) among patients in the Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure trial. Methods and results: Body mass index was analysed by World Health Organization (WHO) categories and as a continuous variable using restricted cubic splines. Body mass index ranged from 15.2 to 50 kg/m2 with a mean value of 29.8 (standard deviation ± 6.1) kg/m2. The proportions, by WHO category, were: normal weight 1343 (21.5%); overweight 2073 (33.1%); Class I obesity 1574 (25.2%); Class II obesity 798 (12.8%); and Class III obesity 415 (6.6%). Compared with placebo, dapagliflozin reduced the risk of the primary outcome to a similar extent across these categories: hazard ratio (95% confidence interval): 0.89 (0.69–1.15), 0.87 (0.70–1.08), 0.74 (0.58–0.93), 0.78 (0.57–1.08), and 0.72 (0.47–1.08), respectively (P-interaction = 0.82). The placebo-corrected change in Kansas City Cardiomyopathy Questionnaire total symptom score with dapagliflozin at 8 months was: 0.9 (−1.1, 2.8), 2.5 (0.8, 4.1), 1.9 (−0.1, 3.8), 2.7 (−0.5, 5.8), and 8.6 (4.0, 13.2) points, respectively (P-interaction = 0.03). The placebo-corrected change in weight at 12 months was: –0.88 (−1.28, –0.47), –0.65 (−1.04, –0.26), –1.42 (−1.89, –0.94), –1.17 (−1.94, –0.40), and –2.50 (−4.4, –0.64) kg (P-interaction = 0.002). Conclusions: Obesity is common in patients with HFpEF and is associated with higher rates of heart failure hospitalization and worse health status. Treatment with dapagliflozin improves cardiovascular outcomes across the spectrum of BMI, leads to greater symptom improvement in patients with obesity, compared with those without, and has the additional benefit of causing modest weight loss.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Adamson, Dr Carly and Kondo, Dr Toru and Jhund, Professor Pardeep and McMurray, Professor John |
| Authors: | Adamson, C., Kondo, T., Jhund, P., de Boer, R. A., Honorio, J. W. C., Claggett, B., Desai, A. S., Gamba, M. A. A., Al Habeeb, W., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S.P., Langkilde, A. M., Lindholm, D., Bachus, E., Litwin, S. E., Martinez, F., Petersson, M., Shah, S. J., Vaduganathan, M., Vinh, P. N., Wilderäng, U., Solomon, S. D., and McMurray, J. J.V. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
| Journal Name: | European Heart Journal |
| Publisher: | Oxford University Press |
| ISSN: | 0195-668X |
| ISSN (Online): | 1522-9645 |
| Published Online: | 27 August 2022 |
| Copyright Holders: | Copyright © 2022 The Authors |
| First Published: | First published in European Heart Journal 43(41): 4406-4417 |
| Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information